Janux Therapuetics announced today that it closed a $56 million Series A financing as it develops its T cell engager technology. Avalon Ventures led the financing round, while new investors OrbiMed and RA Capital Management joined in. Additionally, existing investors Bregua and Correlation Ventures participated. OrbiMed partner Dr. Peter Thompson and RA Capital Management partner […]
